$PHIO
Phio Pharmaceuticals Corp. Stock $phio

$phio Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000168316822007528 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.116M	$1.063M	$932.0K
YoY Change	-32.57%	14.06%	-11.24%
% of Gross Profit
Research & Development	$1.614M	$2.508M	$2.807M
YoY Change	-10.08%	-10.65%	122.78%
% of Gross Profit
Depreciation & Amortization	$15.00K	$15.00K	$19.00K
YoY Change	-25.0%	-21.05%	-5.0%
% of Gross Profit
Operating Expenses	$2.730M	$3.571M	$3.739M
YoY Change	-20.87%	-4.49%	61.86%
Operating Profit		-$3.571M	-$3.739M
YoY Change		-4.49%
Interest Expense			-$3.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$1.000K	-$5.000K	-$3.000K
YoY Change		66.67%
Pretax Income	-$2.731M	-$3.576M	-$3.742M
YoY Change	-20.86%	-4.44%	61.99%
Income Tax
% Of Pretax Income
Net Earnings	-$2.731M	-$3.576M	-$3.742M
YoY Change	-20.86%	-4.44%	61.99%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.26	-$0.28
Diluted Earnings Per Share	-$2.40	-$0.26	-$276.5K
COMMON SHARES
Basic Shares Outstanding	13.67M shares	13.66M shares	13.53M shares
Diluted Shares Outstanding		13.66M shares	13.53M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.78M	$14.48M	$26.53M
YoY Change	-51.03%	-45.4%	57.26%
Cash & Equivalents	$11.83M	$14.53M	$26.53M
Short-Term Investments
Other Short-Term Assets	$665.0K	$893.0K	$921.0K
YoY Change	-0.75%	-3.04%	22.8%
Inventory
Prepaid Expenses		$843.0K
Receivables
Other Receivables
Total Short-Term Assets	$12.45M	$15.38M	$27.45M
YoY Change	-49.67%	-43.98%	55.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$183.0K	$198.0K	$466.0K
YoY Change	37.59%	-57.51%	-22.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$24.00K	$24.00K	$27.00K
YoY Change	-11.11%	-11.11%	35.0%
Total Long-Term Assets	$368.0K	$414.0K	$493.0K
YoY Change	-16.93%	-16.02%	-20.48%
TOTAL ASSETS
Total Short-Term Assets	$12.45M	$15.38M	$27.45M
Total Long-Term Assets	$368.0K	$414.0K	$493.0K
Total Assets	$12.81M	$15.79M	$27.94M
YoY Change	-49.09%	-43.49%	53.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$779.0K	$543.0K	$322.0K
YoY Change	175.27%	68.63%	-56.49%
Accrued Expenses	$1.025M	$1.519M	$2.173M
YoY Change	-61.47%	-30.1%	45.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.939M	$2.194M	$2.495M
YoY Change	-36.8%	-12.06%	11.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$34.89K	$70.00K	$202.0K
YoY Change	-79.48%	-65.35%	-38.79%
Total Long-Term Liabilities	$34.89K	$70.00K	$202.0K
YoY Change	-79.48%	-65.35%	-63.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.939M	$2.194M	$2.495M
Total Long-Term Liabilities	$34.89K	$70.00K	$202.0K
Total Liabilities	$1.974M	$2.264M	$2.697M
YoY Change	-39.04%	-16.05%	-3.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$128.4M	-$125.6M
YoY Change	9.82%
Common Stock	$0.00	$1.000K
YoY Change	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.84M	$13.53M	$25.25M
YoY Change
Total Liabilities & Shareholders Equity	$12.81M	$15.79M	$27.94M
YoY Change	-49.09%	-43.49%	53.2%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$2.731M	-$3.576M	-$3.742M
YoY Change	-20.86%	-4.44%	61.99%
Depreciation, Depletion And Amortization	$15.00K	$15.00K	$19.00K
YoY Change	-25.0%	-21.05%	-5.0%
Cash From Operating Activities	-$2.705M	-$3.526M	-$2.866M
YoY Change	9.47%	23.03%	45.48%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$7.000K	-$30.00K
YoY Change		-76.67%	200.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$7.000K	-$30.00K
YoY Change		-76.67%	200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.000K	-3.000K	0.000
YoY Change	-300.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-2.705M	-3.526M	-2.866M
Cash From Investing Activities	0.000	-7.000K	-30.00K
Cash From Financing Activities	2.000K	-3.000K	0.000
Net Change In Cash	-2.703M	-3.536M	-2.896M
YoY Change	9.34%	22.1%	44.8%
FREE CASH FLOW
Cash From Operating Activities	-$2.705M	-$3.526M	-$2.866M
Capital Expenditures	$0.00	-$7.000K	-$30.00K
Free Cash Flow	-$2.705M	-$3.519M	-$2.836M
YoY Change	9.47%	24.08%	44.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001533040
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation		usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36304
	dei	Entity Registrant Name EntityRegistrantName	Phio Pharmaceuticals Corp.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3215903
	dei	Local Phone Number LocalPhoneNumber	767-3861
	dei	Security12b Title Security12bTitle	Common Stock, par value, $0.0001 per share
	dei	Entity Address Address Line1 EntityAddressAddressLine1	257 Simarano Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
	dei	Entity Address City Or Town EntityAddressCityOrTown	Marlborough
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01752
	dei	City Area Code CityAreaCode	508
	dei	Trading Symbol TradingSymbol	PHIO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13667973	shares
CY2022Q3	us-gaap	Cash Cash	14484000	usd
CY2021Q4	us-gaap	Cash Cash	24057000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	843000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	620000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	15377000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	24727000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	192000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	283000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	198000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	133000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27000	usd
CY2022Q3	us-gaap	Assets Assets	15791000	usd
CY2021Q4	us-gaap	Assets Assets	25170000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	543000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	283000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1519000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2660000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2194000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3068000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	70000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	170000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2264000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3238000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13534996	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13667973	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13667973	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13534996	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139175000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138831000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125649000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116900000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	13527000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21932000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15791000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25170000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2508000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2673000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5398000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6661000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1063000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1066000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3334000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3400000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3571000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3739000	usd
	us-gaap	Operating Expenses OperatingExpenses	8732000	usd
	us-gaap	Operating Expenses OperatingExpenses	10061000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3571000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3739000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8732000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10061000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	225000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3576000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3742000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8749000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9836000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13662857	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13534560	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13628931	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12593569	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13662857	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13534560	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13628931	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12593569	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	21932000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	25000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	186000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2642000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19451000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	83000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2531000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17003000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	103000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3576000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	13527000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	13017000	usd
CY2021Q1	phio	Issuance Of Common Stock Prefunded Warrants And Warrants In Connection With Private Placement Net Of Offering Costs IssuanceOfCommonStockPrefundedWarrantsAndWarrantsInConnectionWithPrivatePlacementNetOfOfferingCosts	12669000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6908000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2146000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3407000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	31400000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	132000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2687000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	28845000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	143000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3742000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	25246000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8749000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9836000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	56000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	55000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	91000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	87000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	372000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	342000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	233000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	220000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	260000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-406000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1141000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	711000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-93000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-97000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9424000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9387000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	0	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	19577000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2146000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	28000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	-0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21723000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9573000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12285000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24107000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14294000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14534000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26579000	usd
CY2022Q3	us-gaap	Cash Cash	14484000	usd
CY2021Q3	us-gaap	Cash Cash	26529000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14534000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26579000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_84E_eus-gaap--NatureOfOperations_zpzLuTIpjIN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_864_zv65hJLGgft3">Nature of Operations</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phio Pharmaceuticals Corp. (“<b>Phio</b>,” “<b>we</b>,” “<b>our</b>” or the “<b>Company</b>”) strives to address the biggest challenges in immuno-oncology by working to create new pathways to a cancer-free future for patients. We are developing therapeutics that leverage our INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient’s immune system while weakening tumor defense mechanisms. With our INTASYL self-delivering RNAi technology, we aim to bring the benefits of RNA therapeutics to the treatment of cancer where other modalities may be ineffective.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company continues to respond to and monitor the ongoing coronavirus pandemic. The Company’s corporate headquarters and research facility have seen limited impact and, during the three and nine months ended September 30, 2022, continued to operate with safety measures in place for the health and well-being of its employees, such as working remotely and flexible scheduling, in accordance with guidance from federal, state and local authorities. The Company believes that the coronavirus pandemic has not had a significant impact on its financial condition and results of operations for the three and nine months ended September 30, 2022. However, the extent to which the coronavirus pandemic may materially impact our financial results and operations will depend on a number of factors, including the availability of supplies and services we rely on, the ability to enroll subjects in our clinical trials, the emergence of variant strains of the coronavirus, the development, availability, and public acceptance of effective treatments and vaccines, and the duration of the coronavirus pandemic, which remain difficult to predict and are highly uncertain.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6937335	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zZ747szQVBJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_862_zPfSQTOANKu7">Use of Estimates in Preparation of Financial Statements</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas subject to estimates and judgement include, among others, those related to the fair value of equity awards, accruals for research and development expenses, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets. On an ongoing basis, we evaluate our estimates and base our estimates on historical experience and other relevant assumptions that we believe are reasonable under the circumstances, including as a result of new information that may emerge concerning the coronavirus pandemic and the ongoing conflict between Russia and Ukraine. Actual results could differ materially from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"/>
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	192000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	283000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	70000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	170000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	202000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	295000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0470	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0470	pure
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	33000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	33000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	99000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	99000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	34000	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	44000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	101000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	110000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	34000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	140000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	35000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	209000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	202000	usd
CY2022Q3	phio	Warrants Exercised Shares WarrantsExercisedShares	0	shares
CY2021Q3	phio	Warrants Exercised Shares WarrantsExercisedShares	0	shares
	phio	Warrants Exercised Shares WarrantsExercisedShares	0	shares
	phio	Warrants Exercised Shares WarrantsExercisedShares	0	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2146000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7229979	shares
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	103000	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	143000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	372000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	342000	usd
CY2022Q3	phio	Research And Development Expense From Contractual Obligations ResearchAndDevelopmentExpenseFromContractualObligations	4000000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
CY2022Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
CY2021Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd

Files In Submission

Name	View Source	Status
0001683168-22-007528-index-headers.html	Edgar Link	pending
0001683168-22-007528-index.html	Edgar Link	pending
0001683168-22-007528.txt	Edgar Link	pending
0001683168-22-007528-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
phio-20220930.xsd	Edgar Link	pending
phio_ex3101.htm	Edgar Link	pending
phio_ex3201.htm	Edgar Link	pending
phio_i10q-093022.htm	Edgar Link	pending
phio-20220930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
phio-20220930_def.xml	Edgar Link	unprocessable
phio-20220930_pre.xml	Edgar Link	unprocessable
phio-20220930_lab.xml	Edgar Link	unprocessable
phio_i10q-093022_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHIO
Phio Pharmaceuticals Corp. Stock $phio

2022 Q4 Form 10-Q Financial Statement

#000168316822007528 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO Phio Pharmaceuticals Corp. Stock $phio

2022 Q4 Form 10-Q Financial Statement

#000168316822007528 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHIO
Phio Pharmaceuticals Corp. Stock $phio